title: Widespread alterations of alpha-synuclein in multiple system atrophy.
abstract: Glial cytoplasmic inclusions (GCI) are the hallmark of multiple system atrophy (MSA), a rare movement disorder frequently associated with autonomic dysfunction. In this study of 21 cases of MSA, GCI were consistently immunoreactive for alpha-synuclein and double-immunostained for ubiquitin and oligodendroglial markers, but not glial fibrillary acidic protein. No statistically significant difference was found in the density of GCI in various brain regions in the two forms of MSA, striatonigral degeneration (SND) and olivopontocerebellar atrophy (OPCA). Postmortem brain samples from 9 cases of MSA were fractionated according to solubility in buffer, Triton-X 100, sodium dodecyl sulfate (SDS), and formic acid, and alpha-synuclein immunoreactivity was measured in Western blots. Total alpha-synuclein immunoreactivity was increased in MSA compared to controls, with no statistically significant difference between SND and OPCA. Most of the increase was due to alpha-synuclein in SDS fractions. In controls this fraction had little or no immunoreactivity. In 7 cases and 4 controls correlations were investigated between quantitative neuropathology and biochemical properties of alpha-synuclein. Surprisingly, the amount of SDS-soluble alpha-synuclein correlated poorly with the number of GCI in adjacent sections. Furthermore, areas with few or no GCI unexpectedly had abundant SDS-soluble alpha-synuclein. These findings provide evidence that modifications of alpha-synuclein in MSA may be more widespread than obvious histopathology. Moreover, these alterations may constitute a biochemical signature for the synucleinopathies.
authors.affiliation: Department of Pathology, Mayo Clinic Jacksonville, Jacksonville, Florida, USA. dickson.dennis@mayo.edu
authors.forename: D W
authors.initials: DW
authors.lastname: Dickson
authors.forename: W
authors.initials: W
authors.lastname: Liu
authors.forename: J
authors.initials: J
authors.lastname: Hardy
authors.forename: M
authors.initials: M
authors.lastname: Farrer
authors.forename: N
authors.initials: N
authors.lastname: Mehta
authors.forename: R
authors.initials: R
authors.lastname: Uitti
authors.forename: M
authors.initials: M
authors.lastname: Mark
authors.forename: T
authors.initials: T
authors.lastname: Zimmerman
authors.forename: L
authors.initials: L
authors.lastname: Golbe
authors.forename: J
authors.initials: J
authors.lastname: Sage
authors.forename: A
authors.initials: A
authors.lastname: Sima
authors.forename: C
authors.initials: C
authors.lastname: D'Amato
authors.forename: R
authors.initials: R
authors.lastname: Albin
authors.forename: S
authors.initials: S
authors.lastname: Gilman
authors.forename: S H
authors.initials: SH
authors.lastname: Yen
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000918:Antibody Specificity; D000943:Antigens, Differentiation / Q000378:metabolism; D001479:Basal Ganglia / Q000378:metabolism / Q000473:pathology; D001921:Brain / Q000378:metabolism* / Q000473:pathology / Q000648:ultrastructure; D002451:Cell Compartmentation; D005260:Female; D006801:Humans; D015151:Immunoblotting; D007150:Immunohistochemistry; D002479:Inclusion Bodies / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D019578:Multiple System Atrophy / Q000378:metabolism*; D009419:Nerve Tissue Proteins / Q000276:immunology / Q000378:metabolism*; D009457:Neuroglia / Q000378:metabolism* / Q000473:pathology / Q000648:ultrastructure; D011699:Putamen / Q000378:metabolism; D013347:Subcellular Fractions / Q000378:metabolism; D051843:Synucleins; D014018:Tissue Distribution; D014452:Ubiquitins / Q000378:metabolism; D051844:alpha-Synuclein
chemical_list: D000943:Antigens, Differentiation; D009419:Nerve Tissue Proteins; C497604:SNCA protein, human; D051843:Synucleins; D014452:Ubiquitins; D051844:alpha-Synuclein